// App-Quantinova.ai

FRI0344 : THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS

Researchers

Presenter

  • M. E. Husni

Principal Investigators

  • D. D. Gladman

  • P. Helliwell

  • F. Van den Bosch

  • C. Tasset

  • L. Meuleners

  • L. Gilles

  • L. Gheyle

  • M. Trivedi

  • M. Alani

  • R. Besuyen

  • P. J. Mease

Medical Centers

  • Cleveland Clinic: Orthopedic and Rheumatologic Institute, Cleveland, OH, United States of America

  • University of Leeds, Leeds, United Kingdom

  • Ghent University Hospital, Ghent, Belgium

  • Galapagos, Mechelen, Belgium

  • LACO, contracted by Galapagos NV, Mechelen, Belgium

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • University of Washington, Washington, United States of America

  • Galapagos, Nv, Leiden, The Netherlands

  • Swedish Medical Centre, Seattle, United States of America

Locations

  • United States

  • Canada

  • United Kingdom

  • Belgium

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Endocrine/metabolic Diseases (ME)

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Musculoskeletal

Disease

  • Pulmonary arterial hypertension

  • Psoriatic arthritis

  • Metabolic syndrome

  • Diabetes

  • Dyslipidemia

  • Hypertension

  • Inflammatory Arthritis

  • Obesity

Biomarkers

  • Body mass index

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Placebo Control

  • Open Label

Phase

  • II

Study Id's

  • NCT03320876

Sponsors

  • Galapagos and Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved